Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
Source ↗
👁 1
💬 0
TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced the appointment of Dr. Nageatte Ibrahim, MD, as Chief Medical Officer. Dr. Ibrahim will serve in a fractional capacity, bringing extensive clinical development and oncology expertise to support the advancement of
Comments (0)